Journal of Cytokine Biology
Open Access

The immune system is an intricate network of cells, tissues, and molecules that works together to defend the body from pathogens, tumors, and harmful substances. While immune activation is crucial for protection, excessive or unregulated immune responses can lead to autoimmune diseases, chronic inflammation, or tissue damage. To prevent such harmful outcomes, the immune system employs various immunoregulatory molecules that modulate immune activity. These molecules act as fine-tuners of the immune response, ensuring that the body responds appropriately to threats while maintaining tolerance to self-antigens. The ability to target these immunoregulatory molecules at the molecular level has become a cornerstone of immunotherapy, with promising implications for treating cancer, autoimmune diseases, and infections [1]. This article explores the role of immunoregulatory molecules and how their modulation can influence immune responses.

Description

Immune checkpoint molecules: key regulators of immune activation

Immune checkpoint molecules are one of the most well-studied classes of immunoregulatory molecules. These molecules are expressed on the surface of immune cells and serve to regulate immune responses by providing inhibitory signals that prevent overactivation of the immune system. Key immune checkpoint receptors include PD-1 (Programmed Cell Death Protein 1), CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), and LAG-3 (Lymphocyte Activation Gene 3), which are primarily expressed on T cells [2].

Under normal conditions, these molecules prevent T cells from attacking healthy tissues by dampening excessive immune responses. However, cancer cells often exploit these checkpoints to evade immune surveillance by expressing ligands such as PD-L1, which binds to PD-1 and suppresses T cell activity. Similarly, CTLA-4 can downregulate T cell activation by competing with CD28 for binding to co-stimulatory molecules on antigen-presenting cells.

The therapeutic manipulation of immune checkpoints has led to the development of immune checkpoint inhibitors, which are designed to block these inhibitory signals and reinvigorate the immune response, particularly in cancer therapy [3]. Drugs like pembrolizumab (anti-PD-1) and ipilimumab (anti-CTLA-4) have shown significant promise in treating various cancers by enhancing T cell activity against tumor cells.

Regulatory T cells (Tregs): Regulatory T cells are another crucial class of immunoregulatory molecules that help maintain immune tolerance and prevent autoimmunity. Tregs suppress the activity of other immune cells through direct cell-cell interactions and the release of immunosuppressive cytokines, such as TGF-β (Transforming Growth Factor-beta) and IL-10. By doing so, Tregs control excessive immune responses to self-antigens and prevent the immune system from attacking the body’s own tissues [4]. Tregs are essential for maintaining a balance between immune activation and immune tolerance, and their dysfunction can result in autoimmune diseases like multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. Conversely, an overabundance of Tregs can contribute to tumor immune evasion by inhibiting anti-tumor immune responses.

Targeting Tregs for therapeutic purposes has been a topic of great interest in both autoimmune disease treatment and cancer immunotherapy. In autoimmune diseases, strategies to deplete or inhibit Tregs can restore immune activity against self-antigens, while in cancer, therapies to block Treg function could enhance anti-tumor immunity.

Cytokines and cytokine receptors modulators of inflammation: Cytokines are small signaling molecules that mediate communication between immune cells and regulate various aspects of immune function, including inflammation, cell differentiation, and immune cell migration [5]. Pro-inflammatory cytokines, such as TNF-α (Tumor Necrosis Factor-alpha), IL-1β, and IL-6, are crucial for initiating immune responses against infections. However, unchecked cytokine production can lead to chronic inflammation, tissue damage, and autoimmune conditions.

The regulation of cytokine activity is therefore critical for maintaining immune homeostasis. Cytokine receptors on immune cells bind to specific cytokines, triggering downstream signaling cascades that influence immune cell behavior. For example, the binding of IL-6 to its receptor on T cells can drive their differentiation into inflammatory Th17 cells, which are implicated in diseases like rheumatoid arthritis and inflammatory bowel disease [6].

Therapeutic strategies targeting cytokines and their receptors are being employed to treat inflammatory diseases. Monoclonal antibodies that neutralize pro-inflammatory cytokines (e.g., anti-TNF-α antibodies like infliximab) have revolutionized the treatment of conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Similarly, cytokine receptor inhibitors are being explored as potential treatments for chronic inflammation and autoimmune disorders [7].

Conclusion

Immunoregulatory molecules are essential for maintaining the delicate balance between immune activation and immune tolerance. From immune checkpoint molecules that regulate T cell activity to cytokines that control inflammation, these molecular regulators ensure that the immune system responds appropriately to threats while preventing damage to healthy tissues. Targeting these molecules has become a powerful strategy in immunotherapy, offering new opportunities for treating a wide range of diseases, including cancer, autoimmune disorders, and chronic inflammation.

Acknowledgement

None

Conflict of Interest

None

1. Warnock JN, Al-Rubeai M (2006) Bioreactor systems for the production of biopharmaceuticals from animal cells. Biotechnol Appl Biochem 45: 1-12.

Indexed at, Google Scholar, Crossref

2. Harding MW, Marques LLR, Howard RJ (2009) Can filamentous fungi form biofilms? Trends Microbiol. 17: 475-480.

Indexed at, Google Scholar, Crossref

3. Kobayashi M, Shimizu S (2000) Nitrile hydrolases. Curr Opin Chem Biol. 4: 95-102.

Indexed at, Google Scholar, Crossref

4. Murphy CD (2012) The microbial cell factory. Org Biomol Chem. 10: 1949-1957.

Indexed at, Google Scholar, Crossref

5. Li XZ, Hauer B, Rosche B (2007) Single-species microbial biofilm screening for industrial applications. Appl Microbiol Biotechnol. 76: 1255-1262.

Indexed at, Google Scholar, Crossref

6. Li Q (2020) Application of Fragment-Based Drug Discovery to Versatile Targets. Front Mol Biosci 7: 180.

Indexed at, Crossref, Google Scholar

7. Ayotte Y,  Murugesan JR,  Bilodeau F, Larda S, Bouchard P, et al. (2017) Discovering Quality Drug Seeds by Practical NMR-based Fragment Screening. Protein Sci 26: 194-195.

Google Scholar